PetVivo's flat year shows how hard veterinary biotech is to commercialize

A wider loss on barely-moved revenue is the kind of result that gets buried on a micro-cap. But PetVivo's fiscal 2026 numbers are a useful read for anyone betting on novel veterinary therapeutics: the science can clear regulators while the business still struggles to convert a clinic-by-clinic sale into scale.

PetVivo posts $1.14M revenue and a wider $10.5M loss for fiscal 2026

The veterinary biotherapeutics maker reported full-year revenue of $1.14 million for the fiscal year ended March 31, 2026, up about 1% year over year.

Sales came from two products, the flagship Spryng with OsteoCushion Technology, an injectable joint treatment, and the newer PrecisePRP line. Distributor sales accounted for roughly $886,000 and direct sales to veterinary clinics about $255,000.

Net loss widened to $10.5 million from $8.4 million a year earlier, as gross margins compressed and operating expenses rose.

On the regulatory side, the company said Health Canada recognized Spryng as an authorized veterinary medical device for commercialization in Canada, opening a second national market. PetVivo also promoted an AI diagnostics effort it calls AgenticPet, citing a 97% accuracy claim that it did not substantiate with trial data in the release.

The commercialization gap is the real risk in vet therapeutics

The approval-to-revenue gap is the story here, and it is not unique to PetVivo.

A device or biologic can pass a regulator and still sit on a slow adoption curve, because the buyer is a veterinarian changing an established treatment protocol one clinic at a time. That is a high-touch, low-velocity sale. Flat revenue against a widening loss is what that looks like on a P&L.

For operators and investors, a few takeaways.

Regulatory wins are necessary, not sufficient

A second-country clearance reads well in a press release. It does not move numbers unless there is a distribution engine behind it. PetVivo's split between distributor and direct revenue suggests it is still figuring out which motion actually scales.

Treat unsubstantiated AI claims as marketing until proven

A 97% accuracy figure with no disclosed validation set is investor-deck framing, not clinical evidence. The operator question is what the model was tested against and whether any vet is making decisions with it.

Balance-sheet pressure shapes strategy

A company posting a $10.5 million loss on roughly $1 million of revenue is managing dilution and runway as much as product. Watch financing activity as closely as sales.

None of this means the science is weak. Injectable joint therapeutics and PRP have real clinical logic. It means the hard part of veterinary biotech is the part that does not make headlines: getting thousands of independent clinics to change what they reach for.

Whether new markets translate into revenue next year

The number to watch is not the Canada clearance. It is whether fiscal 2027 revenue finally inflects, because PetVivo has now stacked a second market, a second product line, and an AI pitch on top of a base that barely grew.

If distributor relationships in Canada and the PrecisePRP ramp do not move the top line meaningfully, the thesis gets harder to defend. If they do, it validates the slow grind as a path rather than a trap.

For the broader category, PetVivo is a small but honest test case: novel veterinary therapeutics live or die on commercialization, not approvals.

Source: PetVivo fiscal 2026 results via GlobeNewswire